[ad_1]
Covid, a final analysis of the phase 3 study of the vaccine Pfizer’s coronavirus shows that «is 95% effective» in preventing infections, even in the elderly, and did not cause serious safety problems, said the company that makes the vaccine.
Pfizer Says Final Trial Analysis Shows Its Covid-19 Vaccine Is 95% Effective With No Safety Concerns, And Will Seek FDA Emergency Use “In A Few Days” https://t.co/fz9KwwcqcT
– Breaking news from CNN (@cnnbrk) November 18, 2020
The company counted 170 cases of coronavirus among the volunteers who participated in the trial. Pfizer said 162 infections occurred in people who received placebo or plain saline injections, while 8 cases were in participants who received the actual vaccine. This works 95 percent effective, Pfizer said. «Efficacy was consistent across all ages, races, and demographics.
BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our # COVID-19 the candidate vaccine has met all primary efficacy endpoints.
– Pfizer Inc. (@pfizer) November 18, 2020
The company plans to apply for authorization for the vaccine in a few days, with the goal of continuing distribution later this year if health regulators allow it. «The results of the study mark an important step in this historic 8-month journey to a vaccine that can help end this devastating pandemicAlbert Bourla, CEO of Pfizer, said in a statement. If the FDA approves the two-dose vaccine, Pfizer said it could have as many as 50 million doses available by the end of the year and up to 1.3 billion by the end of next year.
The efficacy observed in adults over 65 years of age was greater than 94%.»Pfizer and its German partner BioNTech said in a joint statement. The vaccine has been tested in 43,500 people in six countries and there does not appear to be any safety concern at this time.
Last updated: 13:45
© REPRODUCTION RESERVED
[ad_2]
